A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis
- PMID: 24442603
- DOI: 10.1007/s10545-013-9674-3
A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis
Abstract
Background: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTX patients at an initial stage of the disease.
Methods: We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population.
Results: Early systemic signs such as cataract, diarrhea and neonatal cholestatic jaundice were considered strong indicators, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score ≥ 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score ≥ 200, with one very strong or four strong indicators, warranted CYP27A1 gene analysis. In our patients, age at diagnosis was 35.5 ± 11.8 years (mean ± standard deviation), whereas with the diagnostic tool it became 10.6 ± 9.8 years (p < 0.01).
Conclusions: Our suspicion index provides a simple and inexpensive diagnostic tool allowing diagnosis and treatment of CTX before neurological disability occurs.
Comment in
-
Screening for cerebrotendinous xanthomatosis.J Inherit Metab Dis. 2015 Mar;38(2):369. doi: 10.1007/s10545-014-9765-9. Epub 2014 Sep 19. J Inherit Metab Dis. 2015. PMID: 25234588 No abstract available.
Similar articles
-
Clinical and molecular genetic features of cerebrotendinous xanthomatosis in Taiwan: Report of a novel CYP27A1 mutation and literature review.J Clin Lipidol. 2019 Nov-Dec;13(6):954-959.e1. doi: 10.1016/j.jacl.2019.10.001. Epub 2019 Oct 10. J Clin Lipidol. 2019. PMID: 31706903 Review.
-
Clinical, biochemical, and molecular insights into Cerebrotendinous Xanthomatosis: A nationwide study of 100 Turkish individuals.Mol Genet Metab. 2024 Jun;142(2):108493. doi: 10.1016/j.ymgme.2024.108493. Epub 2024 May 13. Mol Genet Metab. 2024. PMID: 38772327
-
[Pathophysiology of cerebrotendinous xanthomatosis].Rinsho Shinkeigaku. 2016 Dec 28;56(12):821-826. doi: 10.5692/clinicalneurol.cn-000962. Epub 2016 Nov 12. Rinsho Shinkeigaku. 2016. PMID: 27840382 Review. Japanese.
-
A case of cerebrotendinous xanthomatosis with massive xanthomas but without a considerable increase in serum cholestanol levels.J Clin Lipidol. 2023 Nov-Dec;17(6):834-838. doi: 10.1016/j.jacl.2023.09.008. Epub 2023 Sep 17. J Clin Lipidol. 2023. PMID: 37777472
-
Cerebrotendinous xanthomatosis: A complex interplay between a clinically and genetically heterogeneous condition.Eur J Neurol. 2025 Jan;32(1):e70006. doi: 10.1111/ene.70006. Eur J Neurol. 2025. PMID: 39760285 Free PMC article.
Cited by
-
Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood.Orphanet J Rare Dis. 2016 Apr 16;11:41. doi: 10.1186/s13023-016-0419-x. Orphanet J Rare Dis. 2016. PMID: 27084087 Free PMC article.
-
Living with Cerebrotendinous Xanthomatosis: Patient, Caregiver, and Expert Perspectives.Adv Ther. 2024 Feb;41(2):467-475. doi: 10.1007/s12325-023-02687-8. Epub 2023 Dec 19. Adv Ther. 2024. PMID: 38110654 Free PMC article.
-
Cerebrotendinous xanthomatosis and infertility: A case report.Clin Case Rep. 2022 Dec 2;10(12):e6661. doi: 10.1002/ccr3.6661. eCollection 2022 Dec. Clin Case Rep. 2022. PMID: 36478971 Free PMC article.
-
The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.J Neurol. 2017 May;264(5):862-874. doi: 10.1007/s00415-017-8440-0. Epub 2017 Mar 21. J Neurol. 2017. PMID: 28324197
-
Spinal cerebrotendinous xanthomatosis: A case report and literature review.Mol Genet Metab Rep. 2021 Feb 3;26:100719. doi: 10.1016/j.ymgmr.2021.100719. eCollection 2021 Mar. Mol Genet Metab Rep. 2021. PMID: 33659184 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical